Navigation Links
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
Date:9/24/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that they have entered into a long-term commercial supply agreement for roluperidone (MIN-101), an investigational compound under development by Minerva, for the treatment of negative symptoms of schizophrenia. Under the terms of the agreement, Catalent will manufacture and package the finished dose form of the drug at its facility in Schorndorf, Germany.

Negative symptoms can persist chronically throughout the lifetime of patients with schizophrenia and contribute to poor quality of life and functional outcomes. No treatment is approved to treat these symptoms in the United States. Minerva is currently conducting a pivotal Phase 3 clinical trial with roluperidone at sites in Europe and the U.S. and could potentially be the first to market.

“Launching any new drug with a partner marks the culmination of many years of hard work and having to overcome challenges, and is a milestone for a project,” commented Dr. Aris Gennadios, President, Catalent Softgel & Oral Technologies. He added, “Catalent has a proven track record in developing new treatments and bringing them to market quickly, efficiently, and in the most patient-friendly dose form; and we are pleased to partner with Minerva Neurosciences on this important potential therapy.”

“We are pleased to be working closely with our partner, Catalent, under a long-term supply agreement for a compound with the potential to treat negative symptoms, one of the leading unmet needs in schizophrenia,” said Rick Russell, President of Minerva Neurosciences.

To date, Catalent has worked with Minerva Neurosciences to undertake the tech transfer from pilot to commercial-scale production. This included analytical methods transfer and validation, process optimization, stability studies, and registration batch manufacturing; as well as packaging studies, and assessing the influence of formulation factors on the product’s critical quality attributes as required in the Quality by Design (QbD) process.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (NASDAQ: NERV), is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: Roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit http://www.minervaneurosciences.com

Read the full story at https://www.prweb.com/releases/catalent_and_minerva_neurosciences_enter_commercial_supply_agreement_for_schizophrenia_drug_roluperidone/prweb16594889.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
2. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
3. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
4. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
5. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
6. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
7. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
8. Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
9. Flexible Filling and Adoption of ‘Ready-to-Use’ Technologies to be Discussed by Catalent Biologics at the Pharma Forum
10. Advantages of Singapore as a Clinical Supply Hub to be Discussed by Catalent at Accelerating Clinical Trials in Asia Conference
11. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... (PRWEB) , ... January 27, 2020 , ... ... announced it has secured financing from strategic investors led by Halma plc ... from existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant ... surgery industry at two recent North American investor forums specializing in medical advancements. ... Medical Technologies & Diagnostics Forum on November 21, 2019 in New York City, ...
(Date:1/22/2020)... ... ... QCDx , a private biotech company that has developed a breakthrough Circulating ... of the proprietary RareScope™ instrument to the Carole and Ray Neag Comprehensive Cancer Center ... “The RareScope can detect and isolate intact and live Circulating Tumor Cells from a ...
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet Products has ... for use in harsh environments inside or outside of the human body. ... or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or operation at ...
Breaking Biology Technology:
(Date:2/14/2020)... ... February 14, 2020 , ... Trial By Fire Solutions, a ... Payment tracking, will be showcasing SimpleTrials at the Summit For Clinical Ops Executives ... Summit last year, the SimpleTrials team has completed full validation of the system ...
(Date:2/11/2020)... ... , ... Modality Solutions, a leading biopharmaceutical cold ... by certification body Intertek. Modality Solutions’ Quality Manager, Hannah Anderson, spearheaded the year-long ... Operating Procedures (SOPs) and created ten new SOPs. Anderson trained staff on the ...
(Date:2/6/2020)... ... February 06, 2020 , ... ... medical device and pharmaceutical trials, announced that Ms. Dorothy Abel has joined ... Dorothy oversees the development and execution of regulatory plans designed to help ...
Breaking Biology News(10 mins):